Neutropenia  >>  tegobuvir (GS 9190)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
tegobuvir (GS 9190) / Gilead
NCT01271790 / 2010-023952-10: A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

Completed
2b
245
US, Europe
Tegobuvir (GS-9190), GS-9451, Pegasys®, Copegus®, Tegobuvir placebo, GS-9451 placebo
Gilead Sciences
Hepatitis C, Chronic
01/13
09/13
NCT01225380 / 2010-020911-35: A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

Checkmark EASL 2012
Apr 2012 - Apr 2012: EASL 2012
Completed
2b
324
US, Canada, Europe
GS-9190, GS-9256, Pegasys®, Copegus®, GS-9190 placebo, GS-9256 placebo
Gilead Sciences
Chronic Hepatitis C Infection
01/13
09/13

Download Options